BrainStorm Cell Therapeutics, an Israeli developer of adult stem cell technologies for neurodegenerative diseases, has received a Notice of Allowance from Israel’s Patent Office for its patent application titled “Isolated Population of Cells, Methods of Generating Same, and Uses Thereof in the Treatment of CNS Diseases.”
The company’s main product is NurOwn, which is used to treat amyotrophic lateral sclerosis (ALS), otherwise known as Lou Gehrig’s disease.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
It may not seem like such a big deal to get approval in Israel since it is such a small country. But every time any nation approves a new medication for use it marks a step forward for the company which developed it.
Also, Israel has a good reputation in the field of medicine.
This patent is held jointly with Ramot, Tel Aviv University’s technology transfer company. It claims neurotrophic factor-secreting cells derived from mesenchymal stem cells, methods for producing those cells, and methods of using those cells for the treatment of neurologic diseases.
“This patent allowance in Israel further extends the geographic reach of our intellectual property, as we are already have received similar claims in the U.S., with additional filings pending elsewhere. Given the origin of this technology at Tel Aviv University and our very strong commitment to our Israeli operations, we are happy that Israel’s Patent Office has also acknowledged the innovation of our NurOwn platform technology, ” stated Tony Fiorino, MD, PhD, BrainStorm’s Chief Executive Officer.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.